NCT06552260 - A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions

GlioblastomaRecurrent GlioblastomaBrain Tumor

Interventions

DRUG

Troriluzole

Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.

Trial Locations (3)

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

RECRUITING

Massachusetts General Hospital Cancer Center, Boston